etrinabdione

Etrinabdione (VCE-004.8) is a semi-synthetic cannabidiol (CBD) derivative and aminoquinone compound developed as an orally active small molecule drug. It acts as a dual agonist of peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid receptor type 2 (CB2), with additional activity on the hypoxia-inducible factor pathway and B55α/AMPK/Sirtuin 1/eNOS signaling axis[1][3][6]. These mechanisms confer potent anti-inflammatory, antifibrotic, neuroprotective, angiogenic, and vasculoprotective effects. Etrinabdione has demonstrated efficacy in preclinical models of multiple sclerosis, scleroderma/systemic sclerosis, ischemic stroke, critical limb ischemia/peripheral artery disease (PAD), and fibrosis by reducing inflammation and promoting tissue repair[1][4][6]. The oral formulation is known as EHP-101.

Brand names

EHP-101EHP101EHP 101

Other names

VCE-004.8VCE004.8VCE 004.8etrinabdione